What lies in-between: C3 glomerulopathy with non-hemolytic renal microangiopathy and an ultra-rare C3 variant-Reference-Cited by-同舟云学术

What lies in-between: C3 glomerulopathy with non-hemolytic renal microangiopathy and an ultra-rare C3 variant

Published:2023-03 Issue:3 Volume:365 Page:286-293
ISSN:0002-9629
Container-title:The American Journal of the Medical Sciences
language:en
Short-container-title:The American Journal of the Medical Sciences

Author:

Jandal Ali,Zhong Weixiong,Gopal Deepak,Horner Vanessa,Frater-Rubsam Leah,Djamali Arjang,Bhutani Gauri

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach;De Vriese;J Am Soc Nephrol,2015

2. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference;Goodship;Kidney Int,2017

3. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies;Servais;Kidney Int,2012

4. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?;Ankawi;BMJ Case Rep,2017

5. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults;Fremeaux-Bacchi;Clinic J Am Soc Nephrol CJASN,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease profiles in the Indigenous Australian population are suggestive of a common complement control haplotype;Infection, Genetics and Evolution;2023-08

2. Cyclophosphamide/eculizumab/mycophenolate-mofetil;Reactions Weekly;2023-04-29